IDEXX Laboratories Q3 Revenue Rises 10%; Comparable EPS Reaches $3.96

What happened

IDEXX Laboratories reported third-quarter 2026 revenue of $1.214 billion, up 10% year over year, and diluted earnings per share of $4.01. Comparable diluted earnings per share reached $3.96, up 22%. The company raised its 2026 revenue and earnings outlook but lowered its operating-margin outlook.

Confirmed

Global impact / market context

Higher revenue and comparable earnings suggest stronger sales and profit growth, while the lower operating-margin outlook points to pressure on the share of sales left after operating costs. The mix matters because cost pressure could limit how much additional revenue flows through to earnings.

Analyst inference

The reported growth was supported by recurring diagnostics revenue, testing-volume gains, customer additions and greater instrument use. However, lower rapid assay volumes and the reduced operating-margin outlook qualify the positive results; investors will weigh growth against the company’s ability to control operating costs.

Analyst inference

What to watch

1. Check subsequent results against the raised 2026 revenue outlook of $4.741 billion–$4.767 billion to see whether sales growth continues at the pace management expects. Confirmed
2. Compare future earnings with the raised 2026 earnings-per-share outlook of $14.96–$15.16; earnings per share is profit allocated to each share. Confirmed
3. Watch whether operating costs constrain profit as sales grow, and whether rapid assay volumes recover, since the article reports lower volumes and a reduced margin outlook. Analyst inference

Evidence

• Original source link unavailable